Dianthus therapeutics, inc. announces pricing of upsized $251 million underwritten public offering

New york and waltham, mass., sept. 09, 2025 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases (“dianthus” or the “company”), today announced the pricing of its previously announced upsized underwritten public offering of 6,487,879 shares of its common stock at a public offering price per share of $33.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,112,121 shares of its common stock at a public offering price of $32.999 per pre-funded warrant. the pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. the aggregate gross proceeds to dianthus from the offering are expected to be approximately $251 million before deducting underwriting discounts and commissions and other offering expenses payable by dianthus, excluding any exercise of the underwriters' option to purchase additional shares. the offering is expected to close on september 11, 2025, subject to the satisfaction of customary closing conditions. in addition, dianthus has granted the underwriters a 30-day option to purchase up to an additional 1,140,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. all of the securities are being offered by dianthus.
DNTH Ratings Summary
DNTH Quant Ranking